Publication | Closed Access

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Hematological MalignancyOncologyRelapsed Multiple MyelomaHematologyMyeloid NeoplasiaNon-inferiority StudyMedicineRadiation OncologyPhase 3Health Sciences